Muscle & Performance

Discovered by Immunologists, Repurposed by Horse Trainers, and Now It May Be a Prodrug

A foundational androgen reference entry. FDA-Approved for Confirmed Hypogonadism. Schedule III Controlled Substance. WADA S1 Absolute Ban. TRAVERSE Trial (NEJM 2023): TRT Does Not Increase Cardiovascular Events in Hypogonadal Men. The TTrials: Sexual Function, Bone Density, Anemia All Improved. The Central Paradox: The Compound That Is Appropriate Medical Treatment at One Baseline Testosterone Level Is Misuse at Another. Aromatization, Estradiol Management, HPTA Suppression, Testicular Atrophy, Fertility, and the Full Monitoring Protocol.

The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.

Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.

GlaxoSmithKline Halted Their Own Drug in 2007 Because It Caused Cancer in Every Animal Species They Tested. The Community Is Still Using It. The Drug Worked. That Is the Entire Problem.

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.

The Most Common Community GHRH Analog — Sold Under Three Names. The DAC Confusion That Has Been Causing Purchasing Errors for a Decade. Why DAC Changes Everything About the Dosing Protocol. The Four Substitutions That Make Mod GRF 1-29 Last Long Enough to Work. How the GHRH Receptor and GHS-R1a Receptors Synergize. Why Teichman 2006 Actually Studied CJC-1295 WITH DAC — Not This Compound. The Empty Stomach Rule Is Not Optional.

The Most Prescribed GH Secretagogue Combination in Clinical Practice — and the One Decision That Changes Everything: DAC or No DAC.

The Pure Active Isomer in Clomid. The Drug That Raised Testosterone as Well as TRT While Preserving Fertility — and Still Failed FDA Approval. The Zuclomiphene Problem: Why the Racemic Mixture Causes Side Effects Pure Enclomiphene Shouldn't. The NDA That Died in 2021. How It Differs from TRT, HCG, and Gonadorelin for Male Hypogonadism. The 2025 Meta-Analysis: +273 ng/dL Testosterone vs Placebo.

The DAC distinction determines whether this is a physiologic pulse strategy or a prolonged GH-axis exposure strategy.

The Most Potent Injectable GHRP. Japan-Approved as a Diagnostic Agent. WADA S2 Banned. The Cortisol Problem That Cuts Against What You're Using It For. The Compound the Community Has Mostly Moved Past — and Why Understanding It Anyway Matters.

The Original GHRP — Discovered 12 Years Before the Receptor It Activates Was Named. The Compound That Proved the Ghrelin System Existed Before Ghrelin Was Found. Why Every Subsequent GHRP Was Designed to Fix GHRP-6's Problems. The Hunger That Arrives in 20 Minutes. Cortisol and Prolactin: How Much, Why It Matters, When to Care. The Unexpected Cytoprotective Signal Via CD36. Why Some Bulkers Prefer It Over Ipamorelin on Purpose.

The Compound Every Secretagogue in this reference Targets. 191 Amino Acids. FDA-Approved for GH Deficiency, HIV Wasting, Short Bowel Syndrome. July 2025: Skytrofa Once-Weekly Now Approved for Adults. The Pulsatile vs Continuous GH Exposure Distinction. IGF-1 as the Surrogate Marker. The Fake HGH Crisis. WADA S2 Absolute Ban. Why Secretagogues (Sermorelin, Ipamorelin, MK-677) Are Different. The Active Malignancy Hard Stop. The Cancer-IGF-1 Question That Never Goes Away.

FDA-Approved for Fertility and Male Hypogonadism. The Most Important Hormone in Post-Cycle Therapy. The Active Ingredient in the Simeons 500-Calorie Diet — a Fraud With Its Own FDA Warning. WADA S2 Banned. A Tumor Marker. Three Completely Different Identities in One Glycoprotein.

Designed as a Research Tool to Bypass IGFBP Regulation. ~100-Fold Reduced Binding-Protein Affinity. 20-30 Hour Half-Life vs IGF-1's 10-15 Minutes. The Most Potent IGF-1 Analog Available. No Controlled Human Trial for Body Composition. No Tumor Selectivity. WADA S2 Banned. A Compound Whose Full Cancer Risk Is Genuinely Unknown.

The Compound Defined by What It Doesn’t Do. Every GHRP Before It Elevated Cortisol and Prolactin. Ipamorelin Was Designed to Produce a Clean GH Pulse Without HPA Axis Activation. Raun et al. 1998: 'The First Selective Growth Hormone Secretagogue.' Why the Community Switched From GHRP-6 to Ipamorelin for Most Applications. The GH Stack Partner. The Empty Stomach Rule. Why Selectivity Matters in Practice.

Amino-acid-derived quaternary ammonium compound involved in mitochondrial fatty-acid transport. Commercial claims are often overstated, but specific forms have clinical evidence for neuropathy, peripheral artery disease, muscle recovery, male infertility, and post-MI cardiac outcomes.

The Most Phase-1-Tested SARM in History. The Problem: Phase 1 Used 0.1-1 mg. The Community Uses 5-20 mg. +1.21 kg Lean Mass at 1 mg in 21 Days. Phase 2 Hip Fracture Trial Positive. HPTA Suppression Dose-Dependent and Documented in Clinical Data. The Dose Gap Between Clinical Trials and Community Use Is the Central Risk Issue. Multiple Elite Athlete Doping Violations Including Canelo Álvarez. WADA S1.2.

MIC injection tradition originates from lipotropic injection protocols developed in bariatric and weight loss medicine

Oral non-peptide ghrelin receptor agonist that increases GH/IGF-1 signaling while carrying appetite, glucose, edema, and lethargy tradeoffs.

The Compound Synthesized in 2024 That Vendors Claim Is Superior to MK-677. 92% Higher Binding Affinity, 18-22 Hour IGF-1 Elevation, Fluorinated Backbone for Metabolic Stability — According to Vendor Specifications. What Independent Published Research Actually Exists: Essentially None. How to Use MK-677’s Clinical Evidence as the Pharmacological Framework While Being Honest That MK-777’s Specific Properties Are Unvalidated. WADA S2. Limitless Capsules.

Mitochondrial-derived peptide studied for AMPK signaling, metabolic stress resilience, and exercise-mimetic pathways.

The Most Clinically Studied SARM. The Phase 3 Trials That Nearly Got It Approved. Why the FDA Said No — and Why It Matters. The Most Modest HPTA Suppression Profile in the SARM Class. The Lowest Hepatotoxicity Signal. The Closest Any SARM Has Come to an FDA Indication. Why Phase 3 Failure Doesn't Mean the Compound Doesn't Work. Jonas Brodin and the NHL Doping Case.

The Selectivity Claim That Doesn't Hold Up in the Only Published Human Trial. Phase 1 Breast Cancer Study: 59% Elevated AST, 45% Elevated ALT. Six or More Published DILI Case Reports — Including Near-Transplant Cholestatic Hepatitis. HPTA Suppression: As Real as Testosterone. WADA S1.2 Absolute Ban. FDA Warnings. The 53% Problem: Only Half of SARM Products Contain What They Claim. Why 'Fewer Side Effects Than Steroids' Doesn't Mean Safe.

Genuinely FDA-Approved for 18 Years. Withdrawn for Commercial Reasons, Not Safety. The Gateway Anti-Aging Peptide for a Decade of Compounding Medicine. Put on Category 2 in 2023. Apparently Returned to Category 1 Before the Broader 2026 Reclassification. The Cleanest Safety Profile of Any GH Secretagogue. The Somatostatin Feedback Ceiling That Makes It Physiologically Impossible to Overdose.

Synthetic small-molecule ERRα/β/γ agonist with large endurance gains in mice, zero human trials, and WADA prohibition ahead of human efficacy data.

SS-31's Sister Compound. Targets the Same Mitochondrial Membrane. Cannot Scavenge Free Radicals. Works Anyway. Which Proves Something Important About How SS-31 Actually Works.

The Only FDA-Approved Mitochondrial Therapeutic. Most Clinical Trials Failed. The Basic Science Is Compelling. All Three of These Things Are True Simultaneously.

The TB-4 Fragment That Has Nothing to Do With Actin. Why ACE Inhibitors Raise Ac-SDKP Levels — and Why That Might Explain Some of Their Anti-Fibrotic Effects. Cardiac and Renal Fibrosis Prevention in Animal Models. Produced in the Body by Prolyl Oligopeptidase Cleaving Thymosin Beta-4. The Fragment With More Published Independent Research Than Its Parent Compound. No Human RCT for Community Use.

The Fragment Every Community Vendor Sells as ‘TB-500.’ The Actin-Sequestering Domain of Thymosin Beta-4. Why the Full 43-AA Protein Is Used in Clinical Trials While the Community Uses a 7-AA Fragment. The Phase 2b Cardiac Trial That Used Full Tβ4. Whether the Fragment Recapitulates the Parent Protein’s Pharmacology. What Actin Sequestration Actually Does in Tissue Repair. Polaris and Limitless Community Formats.

FDA-approved GHRH analog for HIV-associated lipodystrophy, used clinically to reduce visceral adipose tissue via pulsatile GH/IGF-1 signaling.

Most Widely Used Peptide Healing Combination in Community History